Zobrazeno 1 - 10
of 139
pro vyhledávání: '"telitacicept"'
Publikováno v:
Clinical Case Reports, Vol 12, Iss 11, Pp n/a-n/a (2024)
Key Clinical Message We report three cases of IMN from our center, where patients received a single dose of telitacicept after showing no response to conventional treatments. Although one case did not respond, the other two cases achieved complete or
Externí odkaz:
https://doaj.org/article/0208072f3f464451bb3932e4ca065225
Autor:
Jia Wang, Haotao Zheng, Jia Wei, Jiaping Wu, Ziyang Feng, Xueqin Chen, Yangsicheng Liu, Wenxin Qin, Xiude Qin, Fanxin Kong
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Muscle-specific kinase (MuSK) myasthenia gravis (MG) is relatively rare and has a higher incidence of myasthenic crisis compared with other subtypes. However, there is still a lack of effective treatment for refractory MuSK MG. We report the case of
Externí odkaz:
https://doaj.org/article/c2bed5ff8abd4d97bdfcf6c58e9aa07b
Publikováno v:
BMC Pregnancy and Childbirth, Vol 24, Iss 1, Pp 1-7 (2024)
Abstract Background IgA nephropathy (IgAN) is the most common cause of primary glomerulonephritis, with complex pathogenic mechanisms involving abnormal B-cell activation. As a novel biologic agent, telitacicept inhibits both B-lymphocyte stimulating
Externí odkaz:
https://doaj.org/article/ecb7a57717af48acb074d0e86ff545f9
Autor:
Sijia Li, Shuting Deng, Sichun Wen, Siqi Peng, Nan Jiang, Bohou Li, Boxi Chen, Ye Yuan, Qiong Wu, Yiming Tao, Jianchao Ma, Ting Lin, Feng Wen, Zhuo Li, Hao Dai, Renwei Huang, Zhonglin Feng, Zhilian Li, Shuangxin Liu, Lixia Xu
Publikováno v:
Case Reports in Nephrology and Dialysis, Vol 14, Iss 1, Pp 42-47 (2024)
Introduction: Refractory lupus nephritis (LN) causes kidney disease progression and increases the risk of loss of renal function. Due to the high specificity and few side effects of biological agents, they are recommended for the treatment of systemi
Externí odkaz:
https://doaj.org/article/4abf39666ec040f6a83a5b9e251a8c4b
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
ObjectiveTo collect real-world data regarding the attainment of the early-achieved lupus low disease activity state (LLDAS) in systemic lupus erythematosus (SLE) patients receiving telitacicept or belimumab treatment, and identify factors predictive
Externí odkaz:
https://doaj.org/article/9d0386e627774389bff14c672884dee8
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
There is always a lack of effective treatment for highly active refractory generalized myasthenia gravis (GMG). Recently, telitacicept combined with efgartigimod significantly reduces circulating B cells, plasma cells, and immunoglobulin G, which bri
Externí odkaz:
https://doaj.org/article/1c6cfa62db904b38ae0caab7d29e27b7
Autor:
Lanlan Ji, Yan Geng, Xiaohui Zhang, Xuerong Deng, Zhibo Song, Meng Tan, Ying Tan, Chenxue Qu, Zhuoli Zhang
Publikováno v:
MedComm, Vol 5, Iss 4, Pp n/a-n/a (2024)
Abstract Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease associated with B‐cell hyperactivity. Telitacicept is a transmembrane activator, calcium modulator, and cyclophilin ligand interactor‐Fc fusion protein, which can n
Externí odkaz:
https://doaj.org/article/750dce17dbef47acb30f3097bc058b5b
Publikováno v:
European Journal of Medical Research, Vol 28, Iss 1, Pp 1-7 (2023)
Abstract IgA nephropathy (IgAN) is the most common primary glomerular disease in the world, and up to 40% of patients with IgAN develop end-stage renal disease (ESRD). At present, an increasing amount of evidence indicates that the pathogenesis of Ig
Externí odkaz:
https://doaj.org/article/9410f8cf740442cf9db976c374f7c3a2
Publikováno v:
Rheumatology & Autoimmunity, Vol 3, Iss 2, Pp 120-124 (2023)
Abstract Introduction Thrombocytopenia, a common noncriteria manifestation of antiphospholipid syndrome (APS), is severe in approximately one‐third of patients with APS. However, there are no guidelines for treating such thrombocytopenia. B‐cell
Externí odkaz:
https://doaj.org/article/e782f061b1334821855880e3799b1edc
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Granulomatous polyangiitis (GPA) is a rare autoimmune disease that can involve multiple systems throughout the body, including the ear, nose, upper and lower respiratory tracts. It is classified as an antineutrophil cytoplasmic antibody (ANCA)-associ
Externí odkaz:
https://doaj.org/article/d4e787d1b843492c85f57d8934441cbe